Benralizumab

證據等級: L5

預測適應症: 10 個

Benralizumab: From Severe Eosinophilic Asthma to Dermatitis

One-Sentence Summary

Benralizumab (Fasenra) is an anti-IL-5 receptor alpha monoclonal antibody internationally approved for the add-on treatment of severe eosinophilic asthma; it currently holds no marketing authorisation with the Danish Medicines Agency (Laegemiddelstyrelsen). The TxGNN model predicts it may be effective for Dermatitis (specifically atopic dermatitis), with 6 clinical trials and 20 publications currently supporting this research direction. However, the pivotal Phase 2 HILLIER randomised controlled trial was terminated early owing to a lack of clinical efficacy in moderate-to-severe atopic dermatitis, which substantially limits the translational value of this prediction.

Quick Overview

Item	Content
Original Indication	Severe eosinophilic asthma (international approval; not marketed in Denmark)
Predicted New Indication	Dermatitis (atopic dermatitis)
TxGNN Prediction Score	99.16%
Evidence Level	L2
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Benralizumab is a humanised, afucosylated monoclonal antibody that targets the alpha subunit of the IL-5 receptor (IL-5Rα). By blocking IL-5 signalling and simultaneously engaging enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), the drug achieves near-complete depletion of circulating and tissue eosinophils and basophils. This eosinophil-depleting mechanism underpins its established efficacy in severe eosinophilic asthma. Formal mechanistic data from DrugBank are not yet available in this evidence pack; the description above is based on published pharmacological literature. Note: the JSON evidence pack flags mechanism of action (MOA) as a high-severity data gap (DG002) that should be resolved via a DrugBank API query before a full mechanistic analysis is conducted.

Atopic dermatitis (AD) is a chronic Type 2 inflammatory skin disease characterised by impaired skin barrier function, intense pruritus, and immune dysregulation. Eosinophils are prominently elevated in AD skin lesions and contribute to tissue damage, cytokine release, and itch amplification. This tissue eosinophilia provided an apparently reasonable mechanistic rationale — depleting eosinophils might reduce skin inflammation — and explains why the TxGNN knowledge graph assigned a high prediction score, given the proximity of eosinophil-mediated immunoregulation nodes shared between asthma and AD.

In practice, however, the clinical hypothesis was not confirmed. The Phase 2 HILLIER trial (NCT04605094, n=194) was terminated early after benralizumab failed to demonstrate meaningful improvement in established AD endpoints versus placebo. Subsequent mechanistic studies confirmed that benralizumab does successfully deplete IL-5Rα-bearing eosinophils in AD skin lesions (target engagement is achieved), yet this does not translate into clinical benefit. Current evidence suggests that IL-4 and IL-13 — rather than IL-5 — are the dominant type 2 cytokines driving keratinocyte dysfunction and itch in AD, which is why dupilumab (anti-IL-4Rα) succeeds where anti-IL-5Rα therapy does not.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04605094	Phase 2	Terminated	194	HILLIER study: multinational, randomised, double-blind, placebo-controlled 16-week trial with 36-week extension comparing benralizumab vs. placebo in moderate-to-severe AD despite topical treatment. Terminated early due to lack of efficacy.
NCT03563066	Phase 2	Completed	20	Mechanistic investigation of benralizumab in AD: assessed effects on eosinophils, basophils, and innate lymphoid type 2 (ILC2) cells in blood and skin lesions of AD patients.
NCT06734884	Phase 2	Not yet recruiting	96	Efficacy and safety of benralizumab in Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) — a severe cutaneous drug hypersensitivity reaction with prominent eosinophil involvement. Estimated completion: September 2029.
NCT06477653	Phase 2	Recruiting	30	Pilot study of dupilumab as add-on therapy in hypereosinophilic syndrome (HES) after partial response to eosinophil-depleting biologics including benralizumab. Provides context on the limits of single-pathway eosinophil depletion.
NCT04763447	Phase 4	Recruiting	234	Omalizumab withdrawal trial in well-controlled severe allergic asthma with atopic comorbidities; provides context on biologic sequencing strategies in type 2 inflammatory disease.
NCT04126499	Observational	Completed	28	Retrospective observational study of benralizumab in severe eosinophilic asthma (Spanish individualised access programme); real-world demographic and safety data relevant to tolerability profiling.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37178404	2023	RCT	J Eur Acad Dermatol Venereol	HILLIER Phase 2 RCT: benralizumab showed no significant improvement in signs or symptoms of moderate-to-severe AD versus placebo. Key negative evidence.
38695680	2024	Plain language summary	Immunotherapy	Accessible summary of the HILLIER trial confirming the lack of benralizumab efficacy in moderate-to-severe AD across all assessed endpoints.
40781582	2025	Mechanistic study	Clin Transl Allergy	Benralizumab successfully depletes IL-5Rα-bearing eosinophils in AD skin lesions, confirming biological target engagement despite absent clinical benefit.
39234416	2024	Clinical study	J Allergy Clin Immunol: Global	Benralizumab reduces eosinophil-mediated skin inflammation after intradermal allergen challenge in AD patients; supports mechanistic role of eosinophils in allergen response.
31690400	2019	Review	Allergy Asthma Proc	Comprehensive review of immunobiologics (anti-IgE, anti-IL-5, anti-IL-4/13) for severe asthma, AD, and chronic urticaria; contextualises benralizumab’s positioning in type 2 disease.
36270814	2023	Case report	Therapie	Benralizumab-induced interstitial granulomatous dermatitis: a rare paradoxical cutaneous adverse reaction reported in one asthma patient. Safety-relevant for dermatology use.
39600395	2024	Review	Allergologie select	Update on biologics in allergology including anti-IL-5Rα position relative to newer approved agents for AD; notes absence of AD indication for benralizumab.
34642091	2021	Review	Ann Allergy Asthma Immunol	Practical guidance on biologic selection for asthma, AD, urticaria, nasal polyps, and eosinophilic oesophagitis; frames the role of IL-5 vs. IL-4/13 pathway targeting.
38878020	2024	Observational	J Allergy Clin Immunol	Patients receiving benralizumab (or dupilumab/mepolizumab) show lower post-vaccination SARS-CoV-2 antibody titres, indicating IL-5 pathway suppression modestly affects adaptive immune responses.
36411004	2023	Review	Immunol Allergy Clin North Am	Safety review of biologics including benralizumab during pregnancy and lactation in women with asthma, allergic rhinitis, and atopic dermatitis.

Denmark Market Information

Benralizumab is not currently distributed on the Danish market and holds no registered marketing authorisations with the Danish Medicines Agency (Laegemiddelstyrelsen). Internationally, benralizumab is marketed as Fasenra by AstraZeneca and holds a centralised EMA authorisation (EU/1/17/1221), which is nominally valid across EU member states including Denmark. The EMA-approved indication covers add-on maintenance treatment of severe eosinophilic asthma in adults. There is no approved indication for dermatitis under any regulatory jurisdiction.

Marketing Authorisation Number	Product Name	Dosage Form	Approved Indication
No Danish marketing authorisations currently on record	—	—	—

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) available via the EMA for complete safety information.

Based on the published literature identified in this evidence pack, the following safety signals are particularly relevant when considering benralizumab in a dermatology context:

Paradoxical cutaneous reaction: A case report (PMID 36270814) documented benralizumab-induced interstitial granulomatous dermatitis in a patient being treated for asthma. This is a rare but notable adverse effect if the drug were to be considered in dermatology patients.
Reduced vaccine immunogenicity: An observational study (PMID 38878020) demonstrated lower SARS-CoV-2 antibody titres following vaccination in patients on benralizumab, indicating that IL-5Rα suppression modestly attenuates adaptive immune responses. Vaccination timing should be considered.
Parasitic infection risk: Anti-type 2 immunity biologics including benralizumab carry a theoretical increased risk of helminth infections due to suppression of eosinophil-mediated anti-parasitic defence (PMID 38035014). Screening for endemic exposure is advisable before initiation.

Conclusion and Next Steps

Decision: Hold

Rationale: The pivotal Phase 2 HILLIER randomised controlled trial (NCT04605094, n=194) was terminated early, and published results (PMID 37178404) confirmed that benralizumab produced no statistically or clinically meaningful improvement in atopic dermatitis endpoints compared with placebo. Although mechanistic studies confirm successful eosinophil depletion in skin lesions (target engagement), this does not translate into clinical benefit — consistent with evidence that AD is driven primarily by IL-4/IL-13 rather than IL-5. The TxGNN high prediction score most likely reflects structural proximity of immunomodulatory disease nodes in the knowledge graph rather than a clinically actionable biological connection.

To proceed, the following would be needed:

Identification of a biomarker-defined AD subpopulation with a dominant eosinophilic endotype (e.g., very high tissue eosinophilia, elevated serum IL-5) that might selectively respond to IL-5Rα depletion
A formally designed biomarker-enriched Phase 2 proof-of-concept study in this subgroup before further investment
Resolution of the formal MOA data gap (DG002) via DrugBank API and review of the full prescribing information (SmPC) to address the safety data gap (DG001) before any clinical programme proceeds
Regulatory pathway scoping with Laegemiddelstyrelsen, given that the product is not currently marketed in Denmark
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.